Singh Mandeep, Rihal Charanjit S, Lennon Ryan J, Spertus John A, Nair K Sreekumaran, Roger Veronique L
Divisions of Cardiovascular Diseases and Department of Health Sciences Research, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, and the Mayo Clinic and Mid America Heart Institute, Rochester, MN 55905, USA.
Circ Cardiovasc Qual Outcomes. 2011 Sep;4(5):496-502. doi: 10.1161/CIRCOUTCOMES.111.961375. Epub 2011 Aug 30.
BACKGROUND- Although older patients frequently undergo percutaneous coronary interventions (PCI), frailty, comorbidity, and quality of life are seldom part of risk prediction approaches. We assessed their incremental prognostic value over and above the risk factors in the Mayo Clinic risk score. METHODS AND RESULTS- Patients ≥65 years who underwent PCI were assessed for frailty (Fried criteria), comorbidity (Charlson index), and quality of life [SF-36]. Of the 628 discharged [median follow-up of 35.0 months (interquartile range, 22.7 to 42.9)], 78 died and 72 had a myocardial infarction (MI). Three-year mortality was 28% for frail patients, 6% for nonfrail patients. The respective 3-year rates of death or MI were 41% and 17%. After adjustment, frailty [hazard ratio (HR), 4.19 [95% confidence interval (CI), 1.85, 9.51], physical component score of the SF-36 (HR, 1.59; 95% CI, 1.24 to 2.02), and comorbidity, (HR, 1.10; 95% CI, 1.05, 1.16) were associated with mortality. Frailty was associated with mortality/MI (HR, 2.61, 1.52, 4.50). Models with conventional Mayo Clinic risk score had C-statistics of 0.628, 0.573 for mortality and mortality/MI, respectively. Adding frailty, quality of life, and comorbidity, the C-statistic was (0.675, 0.694, 0.671) for mortality and (0.607, 0.587, 0.576) for mortality/MI, respectively. Including frailty, comorbidities and SF-36, conferred a discernible improvement to predict death and death/MI (integrated discrimination improvement, 0.027 and 0.016, and net reclassification improvement of 43% and 18%, respectively). CONCLUSIONS- After PCI, frailty, comorbidity and poor quality of life are prevalent and are associated with adverse long-term outcomes. Their inclusion improves the discriminatory ability of the Mayo Clinic risk score derived from the routine cardiovascular risk factors.
背景——尽管老年患者经常接受经皮冠状动脉介入治疗(PCI),但衰弱、合并症和生活质量很少成为风险预测方法的一部分。我们评估了它们在梅奥诊所风险评分中超出危险因素的增量预后价值。
方法与结果——对接受PCI的65岁及以上患者进行衰弱(弗里德标准)、合并症(查尔森指数)和生活质量[SF-36]评估。在628例出院患者中[中位随访35.0个月(四分位间距,22.7至42.9)],78例死亡,72例发生心肌梗死(MI)。衰弱患者的3年死亡率为28%,非衰弱患者为6%。死亡或MI的3年发生率分别为41%和17%。调整后,衰弱[风险比(HR),4.19[95%置信区间(CI),1.85,9.51]、SF-36的身体成分评分(HR,1.59;95%CI,1.24至2.02)和合并症(HR,1.10;95%CI,1.05,1.16)与死亡率相关。衰弱与死亡率/MI相关(HR,2.61,1.52,4.50)。采用传统梅奥诊所风险评分的模型死亡率和死亡率/MI的C统计量分别为0.628和0.573。加入衰弱、生活质量和合并症后,死亡率的C统计量分别为(0.675,0.694,0.671),死亡率/MI的C统计量分别为(0.607,0.587,0.576)。纳入衰弱、合并症和SF-36后,在预测死亡和死亡/MI方面有明显改善(综合判别改善,分别为0.027和0.016,净重新分类改善分别为43%和18%)。
结论——PCI术后,衰弱、合并症和生活质量差很常见,且与不良长期预后相关。将它们纳入可提高源自常规心血管危险因素的梅奥诊所风险评分的判别能力。